SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Collage with colorful casino chips cards dices representing online gambling poker betting e-gaming entertainment.
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
February 12, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
3d rendering, Business e-mail. Open envelope with cross mark on sheet of paper. Rejected contract, document cancelled, not verified.
Editorial
All the Ways Moderna’s Flu Vaccine Rejection Letter Shocked Us
The FDA issued a rare Refusal-to-File letter to Moderna over its mRNA-based influenza vaccine application, in an unusual move that sent the biotech’s shares tumbling.
February 11, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Hiring collage showing HR checking applicant information
Job Trends
Hiring Outlook: January Brings Year-Over-Year Layoff Decline
Last month, biopharmas let go or projected they would let go of less than 500 people combined, based on BioSpace estimates, down almost 1,000 from January 2025. Still, competition for open jobs remains strong, with employed and unemployed biotech and pharma professionals eyeing their next roles.
February 11, 2026
 · 
4 min read
 · 
Angela Gabriel
Viral vector, gene therapy, DNA delivery. Virus inserting genetic material into a cell nucleus. Gene editing, therapeutic genes, engineering, genetic diseases, dna, CRISPR, biotechnology. Medicine 3D illustration
Gene therapy
In Vivo Is Having a Moment as Cell and Gene Therapy Sector Gathers in San Diego
A recurring theme Tuesday morning at Phacilitate’s Advanced Therapies Week was the quickly emerging potential of in vivo approaches to cell and gene therapy—a trend also reflected in recent investments by Eli Lilly and Regeneron.
February 11, 2026
 · 
4 min read
 · 
Heather McKenzie
Castillo San Felipe del Morro in San Juan, Puerto Rico
Manufacturing
PharmaEssentia Shores Up Supply With $46M Investment in Puerto Rico Plant
The Taiwan-based company is establishing a manufacturing center for the U.S. market.
February 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3d fatty liver disease isolated on pink background. 3d illustration render
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
February 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Earnings
Gilead To Stay ‘Proactive And Disciplined’ With Deals But M&A Not Urgent Priority
With 10 launches planned in the coming quarters, Gilead isn’t feeling the same acquisition urgency as its pharma peers—though the prospect of a takeover isn’t off the table.
February 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Close-up of back skin with urticaria
Immunology and inflammation
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage
The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.
February 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Syringe and a vial above the map of the USA. Illustration of the concept of the vaccination and immunization in the United States
Vaccines
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies
After receiving a letter directly from CBER Director Vinay Prasad, Moderna said the FDA had previously signed off on the use of a licensed flu vaccine as a comparator for a Phase 3 study of mRNA-1010.
February 11, 2026
 · 
4 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS